As a leading service provider in drug discovery and research, BOC Sciences is fully capable and committed to providing one-stop proteolysis targeting molecular drug discovery based on chimeric (PROTAC®). This has become a promising strategy in the field of drug discovery. With a comprehensive and advanced platform, we provide PROTAC molecular discovery package services to customers around the world to meet new drug discovery goals. This includes a variety of services that cover the entire process.
Introduction of PROTAC
PROTAC (protein degradation targeted chimera) is a special protein degradation technology, which uses ubiquitin proteasome pathway, a natural protein degradation pathway in cells, to remove specific proteins that need to be degraded. A PROTAC molecule consists of two key domains: the domain that specifically binds to the target protein that needs to be degraded, and the domain that binds to the E3 ubiquitination ligase, which is linked by a specific linker. Unlike traditional small molecule inhibitors, which can only regulate the activity of target proteins, PROTAC can directly degrade target proteins through the protein destruction mechanism of cells themselves. Intracellular proteins with abnormal structure or function are labeled with polyubiquitin by a series of enzymes, which are then transferred to the proteasome for degradation.
Our Services
- We screen the small molecular compounds with high affinity to the target protein from the compound database by virtual screening technique.
- Linked protein with Linker and E3 recognition ligands to obtain complete PROTAC molecules.
- We will use our professional chemical structure modification platform to provide structural modification services to optimize pharmacological properties and other similar drug properties.
- Structural modifications focus on hydrogen bonding, polar surface area, lipophilicity, shape, molecular weight, reactivity, pKa and detailed modifications will be designed according to the specific properties of PROTAC to meet the specific needs of your project.
Our Advantages
- Advanced equipment and technique
- Experienced scientific team
- Highly reliable and reproducible result
- Data analysis, detailed report with results and discussion
- Quality one-stop service
References:
- Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., ... & Gmaschitz, T. (2019). Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based Protac design. Nature chemical biology, 15(8), 846-846.
- Barranco-Medina, S., Murphy, M., Pelc, L., Chen, Z., Di Cera, E., & Pozzi, N. (2017). Rational Design of Protein C Activators. Scientific reports, 7, 44596.
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
